Novo Nordisk hails ‘remarkable’ weight loss result for dual-acting oral drug in early trial
Novo Nordisk has lifted the lid on a phase 1 trial of its oral amylin and GLP-1 receptor co-agonist, linking the candidate to 13.1% weight loss after 12 weeks—and highlighting the potential for further reductions in longer trials.
Novo Nordisk Inc. was sued Friday by five former employees who say the pharmaceutical company mismanages its $2.3 billion ...
As Novo Nordisk A/S and Eli Lilly and Co. go head-to-head in the U.S. and Chinese glucagon-like peptide-1 receptor agonists ...
Novo Nordisk said the shortage of lower strengths of its diabetes drug Ozempic has deteriorated, with intermittent shortages ...
Sun Pharma of India and Mylan Pharmaceuticals of West Virginia seek FDA approval of generic versions of the popular ...
Denmark’s economy has become intertwined with Novo Nordisk A/S, famous for its fast-selling weight-loss treatments, but the ...
Novo Nordisk A/S (NVO) has shared groundbreaking findings at the European Association for the Study of Diabetes meeting in Madrid ...
Amid an ongoing debate over what role, if any, GLP-1 medications should play in treating children who are still in elementary ...
Novo Nordisk's growth slowed and valuation is high, making it not a buy at current prices despite its strong diabetes and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback